Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer

  • 477 Accesses

  • 19 Citations

Summary

In order to investigate the effect of kefir consumption on mucositis induced by 5-FU based chemotherapy (CT), we monitored the systemic immune response by measurement of the serum proinflammatory cytokine levels and we evaluated the anti-microbial effect of kefir with an agar diffusion method. Forty patients with colorectal cancer were included in this randomized prospective study. On the first 5 days of each CT cycle, the study group received oral lavage with kefir and then swallowed 250 ml of kefir while control group received oral lavage with 0.09% NaCl twice a day. Before and after every cycle of CT, the oral mucosa was assessed. Serum proinflammatory cytokine levels were evaluated before the initiation and after the third and the sixth cycle. Kefir was administered in 99 out of 205 courses. Mucositis developed in 27.3% of the courses given with kefir administration and in 21.7% of the courses given with 0.9% NaCl oral rinses. The difference between the two groups was not statistically significant (p > 0.05). When we compared the serum proinflammatory cytokine levels of the two groups at the baseline and following the third and the sixth cycles, we again found no statistically significant difference (p > 0.05). Kefir consumption at the mentioned doses made no statistically significant effect on serum proinflammatory cytokine levels and on the incidence of mucositis development in cancer patients. Under in vitro conditions, kefir inhibits only Staphylococcus epidermidis.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Sonis S (1997) Oral complications. In: Holland JF, Frei E III, Bast RC Jr (eds) Cancer medicine. 4th edn. Lea & Febiger, Philadelphia, pp 3255–3264

  2. 2.

    Sonis ST, Elting LS, Keefe D et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995–2025 doi:10.1002/cncr.20162

  3. 3.

    Trotti A, Byhardt R, Stetz J et al (2000) Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13–47 doi:10.1016/S0360-3016(99)00559-3

  4. 4.

    National Cancer Institute Common Terminology Criteria for Adverse Events v3.0(CTCAE) (2003) Cancer Therapy Evaluation Program. Released December 2003. http://ctep.info.nih.gov. Cited January 20, 2005

  5. 5.

    Sonis ST, Oster G, Fuchs F et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205

  6. 6.

    Sonis ST, Eilers JP, Epstein JB et al (1999) Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 85:2103–2113 doi:10.1002/(SICI)1097-0142(19990515)85:10<2103::AID-CNCR2>3.0.CO;2-0

  7. 7.

    World Health Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva, Switzerland

  8. 8.

    Hall PD, Benko H, Hogan KR et al (1995) The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol 23:1256–1260

  9. 9.

    Sonis ST, Peterson RL, Edwards LJ et al (2000) Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36:373–381 doi:10.1016/S1368-8375(00)00012-9

  10. 10.

    Epstein JB, Silverman S Jr, Paggiarino DA et al (2001) Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92:875–885 doi:10.1002/1097-0142(20010815)92:4<875::AID-CNCR1396>3.0.CO;2-1

  11. 11.

    Dreizen S, Bodey GP, Valdivieso M (1983) Chemotherapy-associated oral infections in adults with solid tumors. Oral Surg Oral Med Oral Pathol 55(2):113–120 doi:10.1016/0030-4220(83)90164-0

  12. 12.

    Baydar M, Dikilitas M, Sevinc A et al (2005) Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. J Natl Med Assoc 97(8):1161–1164

  13. 13.

    Cevikbas A, Yemni E, Ezzedenn FW et al (1994) Antitumoral, antibacterial and antifungal activities of kefir and kefir grain. Phytother Res 8:78–82 doi:10.1002/ptr.2650080205

  14. 14.

    Serot T, Dousset X, Zucca J et al (1990) Mise en evidence et purification partielle de substances antibacteriennes produites par Leuconostoc mesenteroides et Lactobacillus plantarum isoles de grains de kefyr. Microbiol Alim Nutr 8:71–76

  15. 15.

    Vinderola CG, Duarte J, Thangavel D et al (2005) Immunomodulating capacity of kefir. J Dairy Res 72(2):195–202 doi:10.1017/S0022029905000828

  16. 16.

    Furukawa N, Matsuoka A, Takahashi T et al (1991) Effects of fermented milk on the delayed-type hypersensitivity response and survival in mice bearing Meth-A. Anim Sci Technol 62:579–585

  17. 17.

    Osada K, Nagira K, Teruya K et al (1994) Enhancement of interferon-b production with sphingomyelin from fermented milk. Biotherapy 7:115–123 doi:10.1007/BF01877735

  18. 18.

    Eilers J, Berger A, Petersen M (1988) Development, testing and application of the oral assessment guide. Oncol Nurs Forum 15:325–330

  19. 19.

    Clinical Laboratory Standards Institute (2005) Performance standards for antimicrobial disc susceptibility tests: 15th informational supplement. Report no M100-S15 Wayne

  20. 20.

    Vinderola G, Perdigon G, Duarte J et al (2006) Effects of the oral administration of the exopolysaccharide produced by Lactobacillus kefiranofaciens on the gut mucosal immunity. Cytokine 36(5–6):254–260 doi:10.1016/j.cyto.2007.01.003

  21. 21.

    DeMoreno deLeBlanc A, Matar C, Farnworth E et al (2006) Study of cytokines involved in the prevention of a murine experimental breast cancer by kefir. Cytokine 34(1–2):254–260

  22. 22.

    Rodrigues KL, Caputo LRG, Carvalho JCT et al (2005) Antimicrobial and healing activity ok kefir and kefiran extract. Int J Antimicrob Agents 25(5):404–408 doi:10.1016/j.ijantimicag.2004.09.020

  23. 23.

    Yuksekdag ZN, Beyath Y, Aslim B (2004) Determination of some characteristics coccoid forms of lactic acid bacteria isolated from Turkish kefirs with natural probiotic. Lebenson Wiss Technol 37:663–667 doi:10.1016/j.lwt.2004.02.004

Download references

Author information

Correspondence to D. Derin.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Topuz, E., Derin, D., Can, G. et al. Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer. Invest New Drugs 26, 567–572 (2008). https://doi.org/10.1007/s10637-008-9171-y

Download citation

Keywords

  • Serum proinflammatory cytokines
  • Mucositis
  • Kefir